- Home
- ALXO vs IGI Comparison
ALXO vs IGI Comparison
Compare ALXO & IGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- IGI
- Stock Information
- Founded
- ALXO 2015
- IGI 2009
- Country
- ALXO United States
- IGI United States
- Employees
- ALXO N/A
- IGI N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- IGI Investment Managers
- Sector
- ALXO Health Care
- IGI Finance
- Exchange
- ALXO Nasdaq
- IGI Nasdaq
- Market Cap
- ALXO 93.7M
- IGI 102.0M
- IPO Year
- ALXO 2020
- IGI N/A
- Fundamental
- Price
- ALXO $1.26
- IGI $16.51
- Analyst Decision
- ALXO Strong Buy
- IGI
- Analyst Count
- ALXO 6
- IGI 0
- Target Price
- ALXO $3.30
- IGI N/A
- AVG Volume (30 Days)
- ALXO 424.8K
- IGI 33.9K
- Earning Date
- ALXO 11-07-2025
- IGI 01-01-0001
- Dividend Yield
- ALXO N/A
- IGI 4.79%
- EPS Growth
- ALXO N/A
- IGI N/A
- EPS
- ALXO N/A
- IGI N/A
- Revenue
- ALXO N/A
- IGI N/A
- Revenue This Year
- ALXO N/A
- IGI N/A
- Revenue Next Year
- ALXO N/A
- IGI N/A
- P/E Ratio
- ALXO N/A
- IGI N/A
- Revenue Growth
- ALXO N/A
- IGI N/A
- 52 Week Low
- ALXO $0.40
- IGI $15.13
- 52 Week High
- ALXO $2.27
- IGI $17.79
- Technical
- Relative Strength Index (RSI)
- ALXO 38.76
- IGI 37.67
- Support Level
- ALXO $1.49
- IGI $15.78
- Resistance Level
- ALXO $1.64
- IGI $16.87
- Average True Range (ATR)
- ALXO 0.14
- IGI 0.20
- MACD
- ALXO -0.05
- IGI -0.03
- Stochastic Oscillator
- ALXO 4.13
- IGI 63.48
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About IGI Western Asset Investment Grade Defined Opportunity Trust Inc.
Western Asset Invstm Grd Dfnd Opp Tr Inc operates as a non-diversified closed-end management investment company. Its primary investment objective is to provide current income and then liquidate & distribute substantially all of the Fund's net assets to stockholders. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing at least 80% of its net assets in investment-grade corporate fixed-income securities of varying maturities.